GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Year: 2003
Type: article
Source: PubMed
Authors: Yoon Lee, Aikaterini Vassilakos, Ningping Feng, Viengthong Lam, Hongsheng Xie, Ming Wang, Hongnan Jin, Keyong Xiong, Chenyi Liu, Jim Wright, Aiping Young
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: antisense oligonucleotides, anticancer activity, Burkitt lymphoma, melanoma metastasis, colon adenocarcinoma, pancreatic ductal adenocarcinoma, ovarian adenocarcinoma, breast adenocarcinoma, kidney cancer, glioblastoma, prostate cancer, cervical cancer, tumor growth inhibition, survival extension, anticancer agents
Open Access status: closed
OpenAlex ID: W2108879281
